| Document |
Document Title |
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/234808A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.
|
|
WO/2018/234488A1 |
The present invention relates to cyclopropyl compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their...
|
|
WO/2018/235851A1 |
The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the Nav1.7 and Nav1.8 channels, and which are useful in the treatment or prevention of disorders and diseases in which ...
|
|
WO/2018/236040A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
|
WO/2018/232298A1 |
The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing a fungus
|
|
WO/2018/232094A1 |
Disclosed are compounds of formula (I), (II), (III), and (IV), and pharmaceutically acceptable salts thereof. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of formula (I)...
|
|
WO/2018/229041A1 |
The present invention relates to the compounds of formula (I), or their agriculturally acceptable salts or derivatives as herbicides, wherein the variables are defined according to the description, use of compounds of formula (I) as herb...
|
|
WO/2018/232235A1 |
A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(l-methyl-lH-
indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharma...
|
|
WO/2018/230624A1 |
The present invention provides: a modified nucleic acid monomer compound having a specific backbone, such as a 2-ethylglycerol or methoxymethyl-1,3-propanediol backbone, instead of the ribose or deoxyribose backbone of a nucleoside; and ...
|
|
WO/2018/224063A2 |
The invention provides novel solid forms of elagolix and its esters, optionally with acids or with polymers, method of preparation and use thereof. These solid forms are particularly suitable as intermediates of synthesis of elagolix or ...
|
|
WO/2018/223876A1 |
Provided are a fluorescent probe, a preparation method and application thereof. The fluorescent probe is an addition-activation probe and can be used for specific fluorescent protein labeling, and can also be used for protein quantificat...
|
|
WO/2018/226837A1 |
We describe the use of comparative structural analysis and structure-guided molecular design to develop potent and selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13). We applied a three-step process, starting ...
|
|
WO/2018/225816A1 |
Provided is a novel compound which has pest control activity for agricultural and horticultural use. The present invention provides: a nitrogen-containing heterocyclic compound represented by formula (1) or a salt thereof; and a bacteric...
|
|
WO/2018/226230A1 |
The present invention relates generally to methods for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of a small-molecule autophag...
|
|
WO/2018/226622A1 |
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the presen...
|
|
WO/2018/224060A1 |
The present invention relates to solid forms with an antimicrobial activity comprising a polysaccharide and triiodide, where the triiodide decomposition to iodide and volatile iodine is significantly suppressed by the presence of a stabi...
|
|
WO/2018/221720A1 |
The present invention provides: a heterocyclic compound and an intermediate thereof, the compound having an excellent controlling effect against harmful arthropods and being represented by formula (I) (in the formula, R2 represents a C1-...
|
|
WO/2018/221985A1 |
The present invention provides a novel heterocyclic compound and an organic light emitting element using the same.
|
|
WO/2018/221433A1 |
Provided is a novel compound, and a pharmaceutically acceptable salt thereof, that has an action of reducing blood sugar and the like, and that is useful as a therapeutic and/or preventive medicine for diseases such as diabetes. Provided...
|
|
WO/2018/219281A1 |
Disclosed is a class of 4-pyrimidinediamine small molecular organic compounds or related analogues or pharmaceutically acceptable salts thereof, with the structures thereof as shown in formulae (I)-(VI). Also disclosed are the use of the...
|
|
WO/2018/221604A1 |
The present invention provides a method for industrially producing: a pyrimidine compound having pest control efficacy; 2-[4-(trifluoromethyl)phenyl]ethylamine, which is a production intermediate of the pyrimidine compound; a phenylethyl...
|
|
WO/2018/222918A1 |
Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or amelior...
|
|
WO/2018/221667A1 |
The present invention provides a novel pyrimidine compound represented by Formula [I] and a salt thereof: [in the formula, the symbols are as defined in the specification], which is useful for treating, preventing and/or diagnosing seizu...
|
|
WO/2018/215003A1 |
The invention describes the pyrimidine-based compounds of the general formula I. Described compounds lower the production of the prostaglandin E2. In concentrations lowering production of this factor by 50%, these compounds have no negat...
|
|
WO/2018/216887A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2018/215557A1 |
The present invention relates to a compound of the following general formula (I): (I) in which: - either R represents a group Ri and R' represents a group -ArCy1, or R represents a group -ArCy1 and R' represents a group R1; R1 especially...
|
|
WO/2018/215348A1 |
The present invention relates to a compound of formula 1 and an organic electronic device comprising an organic semiconductor layer, wherein at least one organic semiconductor layer comprises a compound of formula (1), wherein L1 has the...
|
|
WO/2018/214872A1 |
The present invention provides a substituted pyrimidinetrione compound, a composition comprising the compound, and a use thereof. The present invention provides a pyrimidinetrione compound as shown in formula (I) or a crystal form, pharm...
|
|
WO/2018/213258A1 |
The present disclosure provides a method of treating a Merlin-deficient tumor using particular sulfamate inhibitors of Nedd8-activating enzyme. The present disclosure also provides a method of treating Merlin-deficient tumors using parti...
|
|
WO/2018/210992A1 |
The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R5b, and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reacti...
|
|
WO/2018/213140A1 |
Disclosed herein are compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (...
|
|
WO/2018/213150A1 |
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...
|
|
WO/2018/213364A1 |
Histone deacetylases (HDACs) inhibitors are disclosed. The HDACs inhibitors possess cytotoxicities to various cancer cell lines. They are useful for treating a tumor associated with deregulation of the activity of histone deacetylases in...
|
|
WO/2018/210994A1 |
The present invention relates to phenyl derivatives of formula (I) Formula (I) wherein (R1)n, R3, R4 a, R4b, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response compri...
|
|
WO/2018/205916A1 |
The present invention falls within the field of medical chemistry, and in particular relates to an FGFR4 inhibitor as shown in formula II, a preparation method thereof, a pharmaceutical composition comprising the inhibitor, and the use o...
|
|
WO/2018/208181A1 |
The invention relates to 2-amino-5-nitropyridine and barbital co-crystals with an X-ray pattern exhibiting the presence of characteristic interplanar distances amounting to: dhkl 2.966x, 3.5823, 2.9972, 2.9302, 3.0772, 5.2652, 5.7601, 4....
|
|
WO/2018/204164A1 |
Disclosed are compounds of Formula (1), including all stereoisomers, N-oxides, and salts thereof (Formula (1)) wherein K, Z, R2, R3 and m are as defined in the disclosure. Also disclosed are compositions containing the compounds, N-oxide...
|
|
WO/2018/203691A1 |
The present invention relates to a pyrimidine derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer comprising the same as an active ingredient....
|
|
WO/2018/204661A1 |
Compounds that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compos...
|
|
WO/2018/201006A1 |
This invention provides methods of treating inflammatory conditions and autoimmune diseases in a mammal, comprising administering to the mammalian subject in need thereof a therapeutically effective amount of a compound, or pro-drug ther...
|
|
WO/2018/198086A1 |
The present invention relates to a process for the preparation of Elagolix of formula (I) and its pharmaceutically acceptable salts. The present invention also relates to an intermediate of formula (VIII) and its use in preparation of El...
|
|
WO/2018/200833A1 |
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as products containing such compounds, and methods of their use and synthesis. Such compounds have the structure of Formula (I) below: (I) or phar...
|
|
WO/2018/194885A1 |
The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.
|
|
WO/2018/195439A2 |
Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.
|
|
WO/2018/189747A1 |
Present invention relates to an improved process for the preparation of N-(3- ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.
|
|
WO/2018/189212A1 |
The invention relates to non-deliquescent acid addition salts of elagolix with strong acids, for example selected from the group consisting of sulfuric acid and hydrochloric acid, to processes for their preparation and to a pharmaceutica...
|
|
WO/2018/189213A1 |
The invention relates to an amorphous solid dispersion comprising elagolix sodium and at least one silicon-based inorganic compound and to a process for preparing the same. Furthermore, it relates to a pharmaceutical composition comprisi...
|
|
WO/2018/191166A1 |
The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, Syndrome X, obesity, predi...
|
|
WO/2018/184274A1 |
Provided in the present application are a compound for enhancing the spatial coupling of endothelial ion channel complex TRPV4-KCa2.3 and antihypertensive applications of the compound.
|
